Close
The page header's logo
Help
Login
Staff Login
Register
FR
0
Selected 
Invert selection
Deselect all
Deselect all
 Add to Cart
 Click here to refresh results
 Click here to refresh results
Go to Login page
 Hide details
Video Player is loading.

1x

00:00
Current Time 0:00
/
Duration -:-
00:00
00:00
/ 
01:47
Stream Type LIVE
 
1x
  • 2x
  • 1.5x
  • 1x, selected
  • 0.75x
  • 0.5x
  • Chapters
  • descriptions off, selected
  • captions settings, opens captions settings dialog
  • captions off, selected

    This is a modal window.

    The media could not be loaded, either because the server or network failed, or because the format is not supported, or asset is still processing.

    Beginning of dialog window. Escape will cancel and close the window.

    Text
    Background
    Window
    Font Size
    Text Edge Style
    Font Family

    End of dialog window.

  • Get link
  • doctype icon
    Conceptually similar
    AstraZeneca vaccine to remain authorized in Canada
    play button
    CP121635062 | AstraZeneca vaccine to remain authorized in Canada 
    N.S. pauses use of AstraZeneca vaccine
    play button
    CP123262421 | N.S. pauses use of AstraZeneca vaccine 
    AstraZeneca vaccine authorized in Canada
    play button
    CP118971421 | AstraZeneca vaccine authorized in Canada 
    AstraZeneca COVID-19 vaccine now recommended for Canadian seniors
    play button
    CP120124021 | AstraZeneca COVID-19 vaccine now recommended for Canadian seniors 
    Ontario to get more than 250,000 AstraZeneca doses
    play button
    CP123251321 | Ontario to get more than 250,000 AstraZeneca doses 
    Newly eligible people receive Oxford-AstraZeneca vaccine
    play button
    CP121946460 | Newly eligible people receive Oxford-AstraZeneca vaccine 
    AstraZeneca blood clot risk remains low: Tam
    play button
    CP122017117 | AstraZeneca blood clot risk remains low: Tam 
    Manitoba approves different second dose after AstraZeneca COVID-19 vaccine
    play button
    CP124342421 | Manitoba approves different second dose after AstraZeneca COVID-19 vaccine 
    Second-dose choice likely for AstraZeneca recipients: Tam
    play button
    CP123597771 | Second-dose choice likely for AstraZeneca recipients: Tam 
    Newsroom Ready: AstraZeneca vaccine authorized in Canada
    play button
    CP118972171 | Newsroom Ready: AstraZeneca vaccine authorized in Canada 
    Action button
    Placeline/People
    City Vaughan
    Country Canada

    AstraZeneca vaccine's benefits vastly outweigh risks: Sharma

    Health Canada's chief medical adviser Dr. Supriya Sharma says federal regulators are closely monitoring scientific findings about whether the Oxford-AstraZeneca vaccine against COVID-19 can lead to dangerous blood clots in a tiny percentage of recipients. But she says there's clear evidence the vaccine is extremely good at preventing COVID-19 and that vastly outweighs any potential risks. 
    Actions
     Add to collection
     Add to cart
    Information
    Source name: 
    The Canadian Press
    Unique identifier: CP120476771 
    Legacy Identifier: n_COVID-Cda20210323T1400 
    Type: Video 
    Duration: 1m47s 
    Dimensions: 1920px × 1080px     123.11 MB 
    Usage rights: FOR ONE TIME USE ONLY. NO STORAGE FOR FUTURE USE. 
    Create Date: 3/23/2021 2:00:00 PM 
    Display aspect ratio: 16:9 
    Tags
    AstraZeneca
    Canada
    canada government
    Coronavirus
    COVID-19
    doses
    health
    Ontario
    Ottawa
    safety
    vaccine
    vaccines